$ERNA
Eterna Therapeutics Inc. Stock $erna

$erna Overview Financials Valuation SEC Filings Company Website

2024 Q3 Form 10-Q Financial Statement

#000149315224031639 Filed on August 13, 2024

Income Statement

Concept	2024 Q3	2024 Q2
Revenue	$487.0K	$47.00K
YoY Change	854.9%
Cost Of Revenue	-$60.00K	$95.00K
YoY Change	-150.0%
Gross Profit	$547.0K	-$48.00K
YoY Change	-892.75%
Gross Profit Margin	112.32%	-102.13%
Selling, General & Admin	$3.381M	$3.896M
YoY Change	-15.05%	55.22%
% of Gross Profit	618.1%
Research & Development	$1.001M	$987.0K
YoY Change	-31.3%	-37.49%
% of Gross Profit	183.0%
Depreciation & Amortization	$37.00K	$44.00K
YoY Change	85.0%	120.0%
% of Gross Profit	6.76%
Operating Expenses	$2.806M	$4.883M
YoY Change	-48.38%	7.34%
Operating Profit	-$2.259M	-$4.931M
YoY Change	-58.96%	8.4%
Interest Expense	-$1.686M	-$797.0K
YoY Change	1432.73%	-4085.0%
% of Operating Profit
Other Income/Expense, Net	-$24.33M	-$595.0K
YoY Change	25786.17%	-1422.22%
Pretax Income	-$26.59M	-$5.526M
YoY Change	374.94%	22.69%
Income Tax	$12.00K	$3.000K
% Of Pretax Income
Net Earnings	-$26.60M	-$5.500M
YoY Change	375.0%	22.01%
Net Earnings / Revenue	-5462.01%	-11702.13%
Basic Earnings Per Share	-$4.92	-$1.02
Diluted Earnings Per Share	-$4.92	-$1.02
COMMON SHARES
Basic Shares Outstanding	5.411M shares	5.410M
Diluted Shares Outstanding	5.410M shares	5.410M shares

Balance Sheet

Concept	2024 Q3	2024 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.264M	$2.586M
YoY Change	-6.29%	40.54%
Cash & Equivalents	$4.264M	$2.586M
Short-Term Investments
Other Short-Term Assets	$279.0K	$769.0K
YoY Change	-60.14%	-28.13%
Inventory
Prepaid Expenses
Receivables	$187.0K	$228.0K
Other Receivables	$187.0K	$228.0K
Total Short-Term Assets	$4.730M	$3.583M
YoY Change	-32.73%	-7.92%
LONG-TERM ASSETS
Property, Plant & Equipment	$105.0K	$654.0K
YoY Change	-39.31%	238.86%
Goodwill	$2.000M	$2.000M
YoY Change	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$120.0K	$120.0K
YoY Change	-97.03%	-91.27%
Total Long-Term Assets	$2.988M	$42.90M
YoY Change	-93.39%	-0.37%
TOTAL ASSETS
Total Short-Term Assets	$4.730M	$3.583M
Total Long-Term Assets	$2.988M	$42.90M
Total Assets	$7.718M	$46.49M
YoY Change	-85.23%	-1.0%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.193M	$2.193M
YoY Change	49.8%	-18.02%
Accrued Expenses	$1.166M	$2.389M
YoY Change	-76.77%	13.28%
Deferred Revenue
YoY Change
Short-Term Debt	$776.0K	$225.0K
YoY Change	-52.68%	-87.14%
Long-Term Debt Due	$559.0K	$331.0K
YoY Change
Total Short-Term Liabilities	$9.952M	$9.600M
YoY Change	3.39%	33.98%
LONG-TERM LIABILITIES
Long-Term Debt	$32.04M	$8.895M
YoY Change	828.61%	2595.45%
Other Long-Term Liabilities	$84.00K	$84.00K
YoY Change	-99.76%	-99.76%
Total Long-Term Liabilities	$84.00K	$84.00K
YoY Change	-99.78%	-99.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$9.952M	$9.600M
Total Long-Term Liabilities	$84.00K	$84.00K
Total Liabilities	$53.11M	$55.01M
YoY Change	9.09%	27.67%
SHAREHOLDERS EQUITY
Retained Earnings	-$225.8M	-$199.2M
YoY Change	24.89%	13.7%
Common Stock	$27.00K	$27.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$45.39M	-$8.526M
YoY Change
Total Liabilities & Shareholders Equity	$7.718M	$46.49M
YoY Change	-85.23%	-1.0%

Cashflow Statement

Concept	2024 Q3	2024 Q2
OPERATING ACTIVITIES
Net Income	-$26.60M	-$5.500M
YoY Change	375.0%	22.01%
Depreciation, Depletion And Amortization	$37.00K	$44.00K
YoY Change	85.0%	120.0%
Cash From Operating Activities	-$6.285M	-$2.259M
YoY Change	7.8%	-41.63%
INVESTING ACTIVITIES
Capital Expenditures	$19.00K	$249.0K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00
YoY Change
Cash From Investing Activities	-$19.00K	-$249.0K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	3.887M	-22.00K
YoY Change	-54.48%	-107.1%
NET CHANGE
Cash From Operating Activities	-6.285M	-2.259M
Cash From Investing Activities	-19.00K	-249.0K
Cash From Financing Activities	3.887M	-22.00K
Net Change In Cash	-2.417M	-2.530M
YoY Change	-189.19%	-28.93%
FREE CASH FLOW
Cash From Operating Activities	-$6.285M	-$2.259M
Capital Expenditures	$19.00K	$249.0K
Free Cash Flow	-$6.304M	-$2.508M
YoY Change	8.13%	-35.19%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent		usd
CY2023Q2	us-gaap	Revenues Revenues		usd
	us-gaap	Revenues Revenues		usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue		usd
CY2023Q2	us-gaap	Gross Profit GrossProfit		usd
CY2024Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff		usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff		usd
CY2024Q2	ERNA	Loss On Non Controlling Investment LossOnNonControllingInvestment		usd
	ERNA	Loss On Non Controlling Investment LossOnNonControllingInvestment		usd
CY2024Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense		usd
CY2024Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross		usd
	ERNA	Commitment Shares Issued Expense CommitmentSharesIssuedExpense		usd
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal		usd
	ERNA	Non Cash Research And Development In Process Asset Acquisition NonCashResearchAndDevelopmentInProcessAssetAcquisition		usd
	us-gaap	Interest Expense Debt InterestExpenseDebt		usd
	us-gaap	Paid In Kind Interest PaidInKindInterest		usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts		usd
	ERNA	Loss On Non Controlling Investment LossOnNonControllingInvestment		usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment		usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts		usd
	ERNA	Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement		usd
	ERNA	Note Warrants Issued NoteWarrantsIssued		usd
	ERNA	Unpaid Fees Incurred In Connection With The Issuance Of Financing UnpaidFeesIncurredInConnectionWithTheIssuanceOfFinancing		usd
	ERNA	Paid Inkind Interest Added To Convertible Notes Principal PaidInkindInterestAddedToConvertibleNotesPrincipal		usd
	ERNA	Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement		usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid		usd
	ERNA	Initial Measurement Of Right Of Use Assets InitialMeasurementOfRightOfUseAssets		usd
	ERNA	Initial Measurement Of Lease Liability InitialMeasurementOfLeaseLiability		usd
	ERNA	Contingent Consideration For Exacis Asset Acquisition ContingentConsiderationForExacisAssetAcquisition		usd
	ERNA	Issuance Of Common Stock For Exacis Asset Acquisition IssuanceOfCommonStockForExacisAssetAcquisition		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2024-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-11460
	dei	Entity Registrant Name EntityRegistrantName	Eterna Therapeutics Inc.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	31-1103425
	dei	Entity Address Address Line1 EntityAddressAddressLine1	1035 Cambridge Street, Suite 18A
	dei	Entity Address City Or Town EntityAddressCityOrTown	Cambridge
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02141
	dei	City Area Code CityAreaCode	212
	dei	Local Phone Number LocalPhoneNumber	582-1199
	dei	Security12b Title Security12bTitle	Common stock, $0.005 par value per share
	dei	Trading Symbol TradingSymbol	ERNA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2024Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	5410588	shares
	dei	Entity Listing Par Value Per Share EntityListingParValuePerShare	0.005
CY2024Q2	us-gaap	Cash Cash	2586000	usd
CY2023Q4	us-gaap	Cash Cash	7575000	usd
CY2024Q2	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	228000	usd
CY2023Q4	us-gaap	Other Receivables Net Current OtherReceivablesNetCurrent	425000	usd
CY2024Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	769000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1599000	usd
CY2024Q2	us-gaap	Assets Current AssetsCurrent	3583000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	9599000	usd
CY2024Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4095000	usd
CY2023Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	4095000	usd
CY2024Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	654000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	493000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35990000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32781000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	2044000	usd
CY2023Q4	us-gaap	Goodwill Goodwill	2044000	usd
CY2024Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	120000	usd
CY2023Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	120000	usd
CY2024Q2	us-gaap	Assets Assets	46486000	usd
CY2023Q4	us-gaap	Assets Assets	49132000	usd
CY2024Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2193000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	1067000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2389000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1893000	usd
CY2024Q2	us-gaap	Taxes Payable Current TaxesPayableCurrent	7000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	2000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4266000	usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	2216000	usd
CY2024Q2	ERNA	Due To Related Party Current DueToRelatedPartyCurrent	331000	usd
CY2023Q4	ERNA	Due To Related Party Current DueToRelatedPartyCurrent	1205000	usd
CY2024Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	189000	usd
CY2023Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	190000	usd
CY2024Q2	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	225000	usd
CY2024Q2	us-gaap	Liabilities Current LiabilitiesCurrent	9600000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6573000	usd
CY2024Q2	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	8895000	usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	6773000	usd
CY2024Q2	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	50000	usd
CY2023Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	116000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36044000	usd
CY2023Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	32854000	usd
CY2024Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	298000	usd
CY2023Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	392000	usd
CY2024Q2	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	41000	usd
CY2023Q4	us-gaap	Business Combination Contingent Consideration Liability Noncurrent BusinessCombinationContingentConsiderationLiabilityNoncurrent	107000	usd
CY2024Q2	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	84000	usd
CY2023Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	84000	usd
CY2024Q2	us-gaap	Liabilities Liabilities	55012000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	46899000	usd
CY2024Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2023Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.005
CY2024Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	1000000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	156000	shares
CY2024Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	156000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	156000	shares
CY2023Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	156000	shares
CY2024Q2	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	156000	usd
CY2023Q4	us-gaap	Preferred Stock Liquidation Preference Value PreferredStockLiquidationPreferenceValue	156000	usd
CY2024Q2	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1000	usd
CY2024Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.005
CY2024Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2024Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5411000	shares
CY2024Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5411000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5410000	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5410000	shares
CY2024Q2	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue	27000	usd
CY2024Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	190611000	usd
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	189186000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-199165000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-186981000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-8526000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2233000	usd
CY2024Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	46486000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	49132000	usd
CY2024Q2	us-gaap	Revenues Revenues	47000	usd
	us-gaap	Revenues Revenues	94000	usd
CY2024Q2	us-gaap	Cost Of Revenue CostOfRevenue	95000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	156000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	50000	usd
CY2024Q2	us-gaap	Gross Profit GrossProfit	-48000	usd
	us-gaap	Gross Profit GrossProfit	-62000	usd
	us-gaap	Gross Profit GrossProfit	-50000	usd
CY2024Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	987000	usd
CY2023Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	1499000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	2445000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	3173000	usd
CY2024Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3896000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2590000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8211000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6182000	usd
CY2023Q2	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	460000	usd
	us-gaap	Research And Development Asset Acquired Other Than Through Business Combination Written Off ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff	460000	usd
CY2024Q2	us-gaap	Operating Expenses OperatingExpenses	4883000	usd
CY2023Q2	us-gaap	Operating Expenses OperatingExpenses	4549000	usd
	us-gaap	Operating Expenses OperatingExpenses	10656000	usd
	us-gaap	Operating Expenses OperatingExpenses	9815000	usd
CY2024Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4931000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-4549000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-10718000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9865000	usd
CY2024Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-136000	usd
CY2023Q2	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-191000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-66000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-146000	usd
CY2024Q2	ERNA	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	66000	usd
CY2023Q2	ERNA	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	118000	usd
	ERNA	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	66000	usd
	ERNA	Change In Fair Value Of Contingent Consideration ChangeInFairValueOfContingentConsideration	118000	usd
CY2023Q2	ERNA	Loss On Non Controlling Investment LossOnNonControllingInvestment	8000	usd
	ERNA	Loss On Non Controlling Investment LossOnNonControllingInvestment	59000	usd
CY2024Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-797000	usd
CY2023Q2	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	24000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-1583000	usd
	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	25000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-280000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-280000	usd
CY2024Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-595000	usd
CY2023Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	45000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1451000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-50000	usd
CY2024Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-5526000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-4504000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-12169000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-9915000	usd
CY2024Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	3000	usd
CY2023Q2	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	4000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	7000	usd
	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	9000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5529000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4508000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12176000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9924000	usd
CY2024Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000	usd
CY2023Q2	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000	usd
	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	8000	usd
CY2024Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-5537000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-4516000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-12184000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-9932000	usd
CY2024Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.02
CY2024Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.02
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.85
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.85
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.25
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.25
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.90
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.90
CY2024Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5410000	shares
CY2024Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5410000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5303000	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5303000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5410000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5410000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	5215000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	5215000	shares
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-3412000	usd
CY2024Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	423000	usd
CY2024Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5529000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-8526000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	2233000	usd
	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	720000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	705000	usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12176000	usd
CY2024Q2	us-gaap	Stockholders Equity StockholdersEquity	-8526000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	7380000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	208000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	580000	usd
CY2023Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	214000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-4508000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3866000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12107000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	12107000	usd
	us-gaap	Stock Issued During Period Value Acquisitions StockIssuedDuringPeriodValueAcquisitions	208000	usd
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	580000	usd
	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	8000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	903000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9924000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3866000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	3866000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12176000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-9924000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	83000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	42000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	705000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	903000	usd
	ERNA	Commitment Shares Issued Expense CommitmentSharesIssuedExpense	249000	usd
	us-gaap	Equity Method Investment Realized Gain Loss On Disposal EquityMethodInvestmentRealizedGainLossOnDisposal	-11000	usd
	ERNA	Non Cash Research And Development In Process Asset Acquisition NonCashResearchAndDevelopmentInProcessAssetAcquisition	433000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1036000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	83000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	2000	usd
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-1000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	422000	usd
	us-gaap	Paid In Kind Interest PaidInKindInterest	407000	usd
	us-gaap	Amortization Of Financing Costs And Discounts AmortizationOfFinancingCostsAndDiscounts	919000	usd
	ERNA	Loss On Non Controlling Investment LossOnNonControllingInvestment	59000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	-197000	usd
	us-gaap	Increase Decrease In Other Receivables IncreaseDecreaseInOtherReceivables	33000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-734000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-214000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	-1000	usd
	us-gaap	Increase Decrease In Other Noncurrent Assets IncreaseDecreaseInOtherNoncurrentAssets	481000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	1549000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-454000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	995000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-215000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-874000	usd
	us-gaap	Increase Decrease In Due To Related Parties IncreaseDecreaseInDueToRelatedParties	-875000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-95000	usd
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	250000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	225000	usd
	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	80000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6006000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9921000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	350000	usd
	us-gaap	Proceeds From Sale Of Property Plant And Equipment ProceedsFromSaleOfPropertyPlantAndEquipment	4000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-346000	usd
	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1405000	usd
	us-gaap	Payment Of Financing And Stock Issuance Costs PaymentOfFinancingAndStockIssuanceCosts	34000	usd
	ERNA	Proceeds From Issuance Of Common Stock Pursuant To Stock Purchase Agreement ProceedsFromIssuanceOfCommonStockPursuantToStockPurchaseAgreement	320000	usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8000	usd
	us-gaap	Payments Of Dividends Preferred Stock And Preference Stock PaymentsOfDividendsPreferredStockAndPreferenceStock	8000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1363000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	312000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-4989000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-9609000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	11670000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	15541000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6681000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5932000	usd
	us-gaap	Interest Paid Net InterestPaidNet	6000	usd
	us-gaap	Interest Paid Net InterestPaidNet	13000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	2000	usd
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	4000	usd
	ERNA	Note Warrants Issued NoteWarrantsIssued	755000	usd
	ERNA	Unpaid Fees Incurred In Connection With The Issuance Of Financing UnpaidFeesIncurredInConnectionWithTheIssuanceOfFinancing	32000	usd
	ERNA	Paid Inkind Interest Added To Convertible Notes Principal PaidInkindInterestAddedToConvertibleNotesPrincipal	584000	usd
	ERNA	Adjustment To Lease Liability And Right Of Use Asset Due To Remeasurement AdjustmentToLeaseLiabilityAndRightOfUseAssetDueToRemeasurement	4245000	usd
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	18000	usd
	ERNA	Initial Measurement Of Right Of Use Assets InitialMeasurementOfRightOfUseAssets	34410000	usd
	ERNA	Initial Measurement Of Lease Liability InitialMeasurementOfLeaseLiability	34169000	usd
	ERNA	Contingent Consideration For Exacis Asset Acquisition ContingentConsiderationForExacisAssetAcquisition	225000	usd
	ERNA	Issuance Of Common Stock For Exacis Asset Acquisition IssuanceOfCommonStockForExacisAssetAcquisition	208000	usd
CY2024Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2586000	usd
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1837000	usd
CY2024Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	4095000	usd
CY2023Q2	us-gaap	Restricted Cash Current RestrictedCashCurrent	4095000	usd
CY2024Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	6681000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	5932000	usd
	ERNA	Number Of In Licensed Portfolio Patents NumberOfInLicensedPortfolioPatents	100	integer
CY2024Q2	us-gaap	Cash Cash	2600000	usd
CY2024Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-199200000	usd
CY2024Q2	us-gaap	Net Income Loss NetIncomeLoss	-5500000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-12200000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-6000000.0	usd
CY2022Q4	us-gaap	Area Of Real Estate Property AreaOfRealEstateProperty	45500
CY2022Q4	us-gaap	Line Of Credit LineOfCredit	4100000	usd
CY2022Q4	us-gaap	Restricted Cash RestrictedCash	4100000	usd
CY2023Q2	ERNA	Allocated Percentage Of Fair Value Consideration To Purchased License AllocatedPercentageOfFairValueConsiderationToPurchasedLicense	1	pure
CY2023Q3	ERNA	Proceeds From Option And License Agreement ProceedsFromOptionAndLicenseAgreement	300000	usd
CY2023Q3	ERNA	Proceeds From Cell Line Customization Activities ProceedsFromCellLineCustomizationActivities	400000	usd
CY2024Q2	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	1	pure
	us-gaap	Contract With Customer Performance Obligation Satisfied In Previous Period ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod	0	usd
	us-gaap	Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueModificationOfContract	0	usd
CY2023Q2	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
	us-gaap	Contract With Customer Liability Revenue Recognized ContractWithCustomerLiabilityRevenueRecognized	0	usd
	ERNA	Option Fee Obligation Payment Percentage OptionFeeObligationPaymentPercentage	0.20	pure
	ERNA	Proceeds From Option And License Agreement ProceedsFromOptionAndLicenseAgreement	300000	usd
CY2023Q2	ERNA	License Costs LicenseCosts	0	usd
CY2024Q1	us-gaap	Convertible Debt Fair Value Disclosures ConvertibleDebtFairValueDisclosures	3785000	usd
CY2024Q1	ERNA	Allocation Percentage Of Fair Value AllocationPercentageOfFairValue	100.00	pure
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1405000	usd
CY2024Q1	us-gaap	Payments Of Debt Issuance Costs PaymentsOfDebtIssuanceCosts	66000	usd
CY2024Q1	ERNA	Proceeds From Convertible Debt Net ProceedsFromConvertibleDebtNet	1339000	usd
	ERNA	Unpaid Interest On Convertible Notes Principal UnpaidInterestOnConvertibleNotesPrincipal	400000	usd
CY2024Q2	us-gaap	Goodwill Goodwill	2000000.0	usd
CY2024Q2	us-gaap	Accrued Rent Current AccruedRentCurrent	2300000	usd
CY2024Q2	ERNA	Late Fees And Interest Payments Due LateFeesAndInterestPaymentsDue	70000	usd
CY2024Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	1633000	usd
CY2023Q2	us-gaap	Operating Lease Cost OperatingLeaseCost	67000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	3269000	usd
	us-gaap	Operating Lease Cost OperatingLeaseCost	135000	usd
CY2024Q2	us-gaap	Sublease Income SubleaseIncome	21000	usd
CY2023Q2	us-gaap	Sublease Income SubleaseIncome	21000	usd
	us-gaap	Sublease Income SubleaseIncome	42000	usd
	us-gaap	Sublease Income SubleaseIncome	42000	usd
CY2024Q2	us-gaap	Variable Lease Cost VariableLeaseCost	332000	usd
CY2023Q2	us-gaap	Variable Lease Cost VariableLeaseCost	7000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	663000	usd
	us-gaap	Variable Lease Cost VariableLeaseCost	12000	usd
CY2024Q2	us-gaap	Lease Cost LeaseCost	1944000	usd
CY2023Q2	us-gaap	Lease Cost LeaseCost	53000	usd
	us-gaap	Lease Cost LeaseCost	3890000	usd
	us-gaap	Lease Cost LeaseCost	105000	usd
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	32781000	usd
	ERNA	Adjustment To Remeasurement Of Operating Lease Rou Assets AdjustmentToRemeasurementOfOperatingLeaseROUAssets	4245000	usd
	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	1036000	usd
CY2024Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	35990000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	35070000	usd
	ERNA	Adjustment To Lease Liability Due To Remeasurement Of Sublease AdjustmentToLeaseLiabilityDueToRemeasurementOfSublease	4245000	usd
	ERNA	Accretion Of Interest Sublease AccretionOfInterestSublease	1787000	usd
	ERNA	Principal Payments On Operating Lease Liabilities PrincipalPaymentsOnOperatingLeaseLiabilities	-792000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	40310000	usd
CY2024Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	36044000	usd
CY2024Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	4266000	usd
CY2024Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P9Y3M18D
CY2024Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1107	pure
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	5305000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	6075000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6238000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	6308000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	6406000	usd
CY2024Q2	ERNA	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	33879000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	64211000	usd
CY2024Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23901000	usd
CY2024Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	40310000	usd
CY2024Q2	ERNA	Accrued Somerville Facility Current AccruedSomervilleFacilityCurrent	547000	usd
CY2023Q4	ERNA	Accrued Somerville Facility Current AccruedSomervilleFacilityCurrent	218000	usd
CY2024Q2	ERNA	Accrued Legal Fees And Related Current AccruedLegalFeesAndRelatedCurrent	545000	usd
CY2023Q4	ERNA	Accrued Legal Fees And Related Current AccruedLegalFeesAndRelatedCurrent	643000	usd
CY2024Q2	us-gaap	Interest Payable Current InterestPayableCurrent	422000	usd
CY2023Q4	us-gaap	Interest Payable Current InterestPayableCurrent	176000	usd
CY2024Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	229000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	239000	usd
CY2024Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	134000	usd
CY2023Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	109000	usd
CY2024Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	512000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	508000	usd
CY2024Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	2389000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1893000	usd
	ERNA	License Agreement Automatic Renewal Term LicenseAgreementAutomaticRenewalTerm	P5Y
CY2023Q1	ERNA	Percentage Of Sublicense Fees Paid Before License Expiration Date PercentageOfSublicenseFeesPaidBeforeLicenseExpirationDate	0.20	pure
CY2023Q1	ERNA	Related Party Transaction Periodic Fees Payment Amount RelatedPartyTransactionPeriodicFeesPaymentAmount	400000	usd
	ERNA	Notice Period For First Termination Of Contract NoticePeriodForFirstTerminationOfContract	P120D
CY2024Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	423000	usd
CY2023Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	214000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	705000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	903000	usd
CY2024Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	20386000	shares
CY2024Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31076000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31076000	shares
CY2023Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5243000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5243000	shares
CY2024Q2	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2024Q2	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2024Q2	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false

Files In Submission

Name	View Source	Status
0001493152-24-031639-index-headers.html	Edgar Link	pending
0001493152-24-031639-index.html	Edgar Link	pending
0001493152-24-031639.txt	Edgar Link	pending
0001493152-24-031639-xbrl.zip	Edgar Link	pending
erna-20240630.xsd	Edgar Link	pending
erna-20240630_cal.xml	Edgar Link	unprocessable
erna-20240630_def.xml	Edgar Link	unprocessable
erna-20240630_lab.xml	Edgar Link	unprocessable
ex10-1.htm	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
form10-q_001.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
erna-20240630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ERNA
Eterna Therapeutics Inc. Stock $erna

2024 Q3 Form 10-Q Financial Statement

#000149315224031639 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ERNA Eterna Therapeutics Inc. Stock $erna

2024 Q3 Form 10-Q Financial Statement

#000149315224031639 Filed on August 13, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ERNA
Eterna Therapeutics Inc. Stock $erna